Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 22,500 Shares of Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 22,500 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the sale, the insider now owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Neurocrine Biosciences, Inc. (NBIX) traded down 0.28% during mid-day trading on Tuesday, reaching $53.65. The company’s stock had a trading volume of 1,058,024 shares. The company’s market capitalization is $4.73 billion. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $55.38. The stock has a 50-day moving average price of $47.37 and a 200-day moving average price of $46.32.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same quarter last year, the firm posted ($0.46) earnings per share. Equities research analysts forecast that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.
A number of hedge funds have recently made changes to their positions in NBIX. Dimensional Fund Advisors LP raised its stake in shares of Neurocrine Biosciences by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 165,953 shares of the company’s stock worth $6,422,000 after buying an additional 4,428 shares during the last quarter. Teachers Advisors LLC raised its stake in Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock worth $3,030,000 after buying an additional 4,668 shares in the last quarter. Capstone Asset Management Co. bought a new stake in Neurocrine Biosciences during the first quarter worth $214,000. Quantitative Systematic Strategies LLC bought a new stake in Neurocrine Biosciences during the first quarter worth $261,000. Finally, Columbus Circle Investors raised its stake in Neurocrine Biosciences by 33.3% in the first quarter. Columbus Circle Investors now owns 207,699 shares of the company’s stock worth $8,993,000 after buying an additional 51,872 shares in the last quarter. 96.48% of the stock is currently owned by institutional investors.
A number of analysts recently commented on NBIX shares. Bank of America Corporation started coverage on Neurocrine Biosciences in a research report on Friday, May 5th. They set a “buy” rating and a $70.00 price objective for the company. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Jefferies Group LLC upped their price objective on Neurocrine Biosciences from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, April 12th. Leerink Swann reduced their price objective on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research report on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $68.25.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.